ReviewToxins2018
Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins.
Review in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 51 citations in OpenAlex.
- Ribosome-Inactivating Proteins fromBiomedicines · 2026Article
- A proimmunotoxin nanodrug targeting AIDS-associated non-Hodgkin lymphoma.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Improving Cytotoxicity of Saporin with Saponin SO1406 Isolated from the Roots of Saponaria Officinalis.Biomedicines · 2026Article
- Enhanced Antitumor Efficacy of a Combination of Immunotoxin and Photosensitizer Under Illumination in Xenograft Mice.Biomedicines · 2026Article
- Targeted depletion of dysfunctional hematopoietic stem cells mitigates myeloid-biased differentiation in aged mice.Cell discovery · 2025Article
- Next generation targeted non-genotoxic conditioning for hematopoietic stem cell and hematopoietic stem cell-based gene therapy.Frontiers in immunology · 2025Review
- Mutational Analysis of RIP Type I Dianthin-30 Suggests a Role for Arg24 in Endocytosis.Toxins · 2024Article
- Cetuximab-Toxin Conjugate and NPe6 with Light Enhanced Cytotoxic Effects in Head and Neck Squamous Cell Carcinoma In Vitro.Biomedicines · 2024Article
- Self-Assembly of Epitope-Tagged Proteins and Antibodies for Delivering Biologics to Antigen Presenting Cells.Journal of the American Chemical Society · 2024Article
- Antibody-drug conjugates: Recent advances in payloads.Acta pharmaceutica Sinica. B · 2023Review
- New Insights on Saporin Resistance to Chemical Derivatization with Heterobifunctional Reagents.Biomedicines · 2023Article
- Development of a new minimally invasive phototherapy for lung cancer using antibody-toxin conjugate.Thoracic cancer · 2023Article
- Review
- Tumor-specific intracellular delivery: peptide-guided transport of a catalytic toxin.Communications biology · 2023Article
- Plant-Derived Type I Ribosome Inactivating Protein-Based Targeted Toxins: A Review of the Clinical Experience.Toxins · 2022Review
- Saporin Toxin Delivered by Engineered Colloidal Nanoparticles Is Strongly Effective against Cancer Cells.Pharmaceutics · 2022Article
- Research Progress of Conjugated Nanomedicine for Cancer Treatment.Pharmaceutics · 2022Review
- Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage.Biomedicines · 2022Article
- Review
- A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant Ribosome-inactivating proteins (RIPs) including the type I RIP Saporin have been used for the construction of Immunotoxins (ITxs) obtained via chemical conjugation of the toxic domain to whole antibodies or by generating genetic fusions to antibody fragments/targeting domains able to direct the chimeric toxin against a desired sub-population of cancer cells. The high enzymatic activity, stability and resistance to conjugation procedures and especially the possibility to express recombinant fusions in yeast, make Saporin a well-suited tool for anti-cancer therapy approaches. Previous clinical work on RIPs-based Immunotoxins (including Saporin) has shown that several critical issues must be taken into deeper consideration to fully exploit their therapeutic potential. This review focuses on possible combinatorial strategies (chemical and genetic) to augment Saporin-targeted toxin efficacy. Combinatorial approaches may facilitate RIP escape into the cytosolic compartment (where target ribosomes are), while genetic manipulations may minimize potential adverse effects such as vascular-leak syndrome or may identify T/B cell epitopes in order to decrease the immunogenicity following similar strategies as those used in the case of bacterial toxins such as Pseudomonas Exotoxin A or as for Type I RIP Bouganin. This review will further focus on strategies to improve recombinant production of Saporin-based chimeric toxins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.